Welcome to our dedicated page for Clearmind Medici news (Ticker: CMND), a resource for investors and traders seeking the latest updates and insights on Clearmind Medici stock.
Clearmind Medicine Inc. develops clinical-stage neuroplastogen-derived therapeutics focused on mental health and substance-use disorders. News for CMND centers on CMND-100, the company's proprietary non-hallucinogenic MEAI-based oral drug candidate for Alcohol Use Disorder, including clinical-trial safety, tolerability, pharmacokinetic and preliminary efficacy updates from a multinational Phase I/IIa study.
Company updates also cover intellectual-property activity for psychedelic and neuroplastogen compounds, including patent applications and licensed development rights tied to PTSD and other mental health disorders. Additional recurring themes include FDA-related clinical communications, data-safety monitoring reviews, clinical-site progress and scientific presentations around MEAI.
Clearmind Medicine Inc. (CMND) has successfully closed an underwritten public offering of 1,153,847 common shares at a price of US$6.50 each, raising gross proceeds of US$7.5 million. This offering follows a 1-for-30 reverse stock split effective September 30, 2022. Aegis Capital Corp. has a 45-day option to purchase up to 173,077 additional shares, potentially bringing total proceeds to about US$8.6 million. The company focuses on developing novel psychedelic-derived therapeutics for major health issues, supported by a robust intellectual property portfolio.